Ionis (NASDAQ: IONS) EVP Kordasiewicz discloses stock and RSU stake
Rhea-AI Filing Summary
Ionis Pharmaceuticals executive Holly B. Kordasiewicz, EVP and Chief Development Officer, filed an initial ownership report showing her equity stake in the company. She directly holds 7,740 shares of Ionis common stock.
She also holds multiple non-qualified stock options to buy Ionis common stock, including grants covering 12,000, 10,000, 11,500, 19,800, 19,895 and 28,951 shares with exercise prices ranging from $32.60 to $60.89 and expiration dates between 2027 and 2035.
In addition, Kordasiewicz has 31,949 restricted stock units (RSUs). These RSUs were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan on January 15 of 2022, 2023, 2024 and 2025, and vest in four equal annual installments, settling in Ionis common shares or cash as determined by the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. Grants to reporting person of restricted stock units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan on January 15, 2022, January 15, 2023, January 15, 2024, and January 15, 2025. The restricted stock units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
FAQ
What does Ionis Pharmaceuticals (IONS) Form 3 for Holly B. Kordasiewicz show?
The Form 3 shows that Holly B. Kordasiewicz, EVP and Chief Development Officer of Ionis Pharmaceuticals, reported her initial beneficial ownership, including 7,740 shares of common stock, several tranches of non-qualified stock options, and 31,949 restricted stock units (RSUs).
What stock options does Holly B. Kordasiewicz hold in Ionis Pharmaceuticals?
The filing lists several non-qualified stock options to purchase Ionis common stock: 12,000, 10,000, 11,500, 19,800, 19,895 and 28,951 shares with exercise prices between $32.60 and $60.89 and expiration dates from 2027 through 2035, all held directly.
How many restricted stock units does Holly B. Kordasiewicz have from Ionis (IONS)?
Holly B. Kordasiewicz holds 31,949 restricted stock units (RSUs), each representing a contingent right to receive one share of Ionis common stock or its equivalent cash value.
What are the vesting terms of Holly B. Kordasiewicz’s RSUs at Ionis Pharmaceuticals?
The RSUs were granted on January 15, 2022, 2023, 2024, and 2025 under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. They vest in four equal annual installments, and upon vesting will be paid in whole Ionis common shares or cash, as determined by the company.